


Fighting MDR-TB with Bedaquiline

480,000*cases of multidrug-resistant tuberculosis (MDR-TB) every year





Current MDR-TB treatment is





Bedaquiline, the first new drug to treat TB in more than 40 years, brings **new hope** to patients fighting MDR-TB with little to no other treatment options.

The bedaquiline donation program is an innovative public-private partnership between USAID and Janssen Therapeutics of Johnson & Johnson. The donation of bedaquiline, combined with technical support provided by USAID, will enable patients in nearly 100 countries to access this life-saving medication and fight MDR-TB.